Matrushri
Fertility Centers Consultancy (Agencies)
PGT-A · PGT-M · PGT-SR — Chromosomally Normal Embryos Only
Matrushri's Genetics Program uses cutting-edge DNA analysis to test embryos before transfer — selecting only chromosomally normal, genetically healthy embryos for the highest chance of a successful, healthy pregnancy.
Preimplantation Genetic Testing (PGT) — formerly known as Preimplantation Genetic Screening (PGS) or Preimplantation Genetic Diagnosis (PGD) — is an advanced technique performed during an IVF cycle that analyses the genetic makeup of embryos before they are transferred to the uterus.
💡 The Core Concept: Most IVF embryos that fail to implant or result in miscarriage do so because of chromosomal abnormalities (aneuploidy). PGT identifies these abnormal embryos before transfer — so only chromosomally normal (euploid) embryos are selected, dramatically improving success rates and reducing the heartbreak of failed cycles and pregnancy loss.
A small biopsy of 5–10 cells is taken from the outer layer (trophectoderm) of the blastocyst on Day 5 or 6. The embryo itself is vitrified while the biopsy is analysed using Next Generation Sequencing (NGS) — the most accurate and comprehensive genetic testing technology available. Results are available within 7–14 days, after which the best embryo is selected for a frozen embryo transfer (FET).
Matrushri's Genetics Program covers all three types of PGT — PGT-A, PGT-M, and PGT-SR — performed in partnership with certified genetic laboratories using state-of-the-art NGS technology.
Each type of PGT serves a distinct clinical purpose. Your specialist will recommend the appropriate test based on your medical history and risk factors.
PGT-A (formerly called PGS — Preimplantation Genetic Screening) tests all 23 pairs of chromosomes in each embryo to identify those with the correct number (euploid) versus those with extra or missing chromosomes (aneuploid).
Chromosomal aneuploidy is the leading cause of failed IVF implantation and early pregnancy loss. By selecting only euploid embryos, PGT-A significantly improves outcomes and reduces the number of cycles needed.
Using Next Generation Sequencing (NGS) — the most advanced and accurate technology available — our genetics program analyses all 24 chromosomes from every biopsied blastocyst with >99% accuracy.
PGT-M (formerly called PGD — Preimplantation Genetic Diagnosis) screens embryos for specific inherited single-gene (monogenic) disorders where one or both parents are known carriers or affected individuals.
When both parents carry a recessive gene mutation (e.g. thalassaemia, cystic fibrosis), each pregnancy has a 25% chance of being affected. PGT-M eliminates this risk before pregnancy begins, allowing carrier couples to have an unaffected child.
Each PGT-M case is unique — our genetic counsellors and partner laboratory design a bespoke probe for your specific mutation before the IVF cycle begins. We support families with thalassaemia, sickle cell disease, cystic fibrosis, Huntington's disease, BRCA1/2 mutations, and many more.
PGT-SR is used when one or both partners carry a structural chromosome rearrangement — such as a balanced translocation or chromosomal inversion. These rearrangements do not typically affect the carrier's health but dramatically increase the risk of miscarriage and chromosomally unbalanced pregnancies.
Carriers of balanced translocations face a very high rate of pregnancy loss — sometimes 60–80%. PGT-SR identifies balanced or normal embryos, transforming fertility outcomes for these families.
Balanced translocation carriers often experience years of recurrent miscarriage before receiving a diagnosis. Our genetics team provides comprehensive karyotyping, genetic counselling, and PGT-SR to break this cycle — offering the realistic prospect of a healthy, chromosomally balanced pregnancy.
From your first genetics consultation to your embryo transfer — every step is managed by our specialist team.
A genetics consultation reviews your medical and family history. For PGT-M/SR, both partners undergo karyotyping and carrier testing. For PGT-A, baseline fertility investigations are completed. A personalised PGT plan is designed — including which type of test is appropriate.
Weeks Before IVFThe female partner undergoes standard IVF ovarian stimulation, egg retrieval, and fertilisation (IVF or ICSI). The goal is to obtain enough blastocysts to maximise the chances of having at least one euploid (or unaffected) embryo for transfer.
Days 0–5 of IVF CycleEmbryos are cultured to the blastocyst stage in our Class 1000 incubators. Only blastocysts (Day 5–6) are suitable for PGT biopsy — making extended culture an essential part of the genetics program.
Day 5–6Our expert embryologist removes 5–10 cells from the trophectoderm (outer layer) of each blastocyst using a laser-assisted microsurgical technique. This does not harm the embryo or its inner cell mass. Each biopsied blastocyst is immediately vitrified (frozen) while awaiting results.
Day 5–6 — Same Day as BiopsyBiopsy samples are sent to our certified partner genetics laboratory for Next Generation Sequencing (NGS) analysis. For PGT-A: all 24 chromosomes are analysed. For PGT-M: the specific gene mutation is targeted. For PGT-SR: structural rearrangements are identified. Results are reported within 7–14 days.
7–14 DaysYour specialist and genetic counsellor review your results with you in detail — explaining each embryo's genetic status, quality grade, and the recommended transfer priority. You make an informed decision about which embryo to transfer first.
Results ConsultationThe best euploid (or unaffected) embryo is thawed and transferred to a prepared uterine lining in a frozen embryo transfer cycle. Pregnancy is confirmed by blood test 14 days later. Remaining suitable embryos remain safely vitrified for future attempts.
FET Cycle — Next MonthOur program covers a comprehensive range of chromosomal and genetic conditions — from common to rare.
Extra or missing chromosomes — the most common cause of failed IVF and miscarriage. Includes trisomies (21, 13, 18) and monosomies (Turner syndrome, 45X).
PGT-AThe most common inherited blood disorder in India. Beta-thalassaemia major requires lifelong transfusions — PGT-M allows carrier couples to have unaffected children.
PGT-MAutosomal recessive haemoglobin disorder causing severe pain crises and organ damage. PGT-M identifies unaffected embryos from carrier parents.
PGT-MThe most common life-limiting autosomal recessive condition in some populations — causing progressive lung and digestive damage. Detectable by PGT-M.
PGT-MAutosomal dominant progressive neurological disorder. PGT-M allows carriers to have unaffected children without the ethical dilemma of prenatal testing after pregnancy.
PGT-MAutosomal recessive neuromuscular disorder — the leading genetic cause of infant death. Carrier couples identified by testing can use PGT-M to have unaffected children.
PGT-MHereditary breast and ovarian cancer gene mutations. PGT-M enables BRCA carriers to have children who do not inherit the increased cancer risk.
PGT-MChromosomal rearrangements carried by one partner that cause a high rate of miscarriage and unbalanced pregnancies. PGT-SR selects chromosomally balanced embryos.
PGT-SRInverted chromosome segments that can produce unbalanced gametes, leading to recurrent miscarriage. PGT-SR identifies embryos with balanced chromosomes.
PGT-SRThe most common inherited cause of intellectual disability. Female premutation carriers can use PGT-M to avoid passing full mutations to their children.
PGT-MX-linked bleeding disorders. PGT-M tests for the specific factor VIII or IX gene mutation, preventing transmission to male offspring from carrier mothers.
PGT-MSevere X-linked muscular dystrophy affecting boys. Female carriers can use PGT-M to ensure only unaffected embryos are transferred — preventing this devastating condition.
PGT-MPGT transforms IVF outcomes by removing the guesswork — and replacing it with certainty.
Euploid embryos implant at 60–70% per transfer — dramatically higher than unselected embryos (~30–40%). Every transfer of a PGT-tested embryo is a high-probability event.
↑ 70% Euploid implantation rate per transferThe miscarriage rate for euploid embryo transfers is approximately 10% — compared to 25–40% for unselected transfers. PGT protects couples from the physical and emotional devastation of pregnancy loss.
↓ 50% Miscarriage rate with euploid transferBy avoiding transfers of embryos destined to fail, PGT-A reduces the total number of IVF cycles needed to achieve a live birth — saving time, money, and emotional cost.
Fewer Cycles needed to achieve live birthChromosomally normal embryos result in healthier pregnancies and babies. For PGT-M, it prevents transmission of devastating inherited conditions — giving your child a healthy start.
Genetic Disease prevention for future generationsWhen we know an embryo is euploid, we can confidently transfer just one — achieving excellent pregnancy rates while eliminating the risks of twin or triplet pregnancies.
eSET Safe single embryo transfer possiblePGT results give you and your specialist complete information about each embryo — removing uncertainty and empowering truly informed decisions about your treatment and family planning.
100% Information before every transferPGT is a powerful tool — but it is most beneficial in specific clinical situations. Your specialist will advise whether it is right for you.
The rate of chromosomal aneuploidy in embryos increases dramatically with age — from ~25% at 35 to >50% at 40 and >70% at 43. PGT-A identifies the normal embryos from an age-affected pool.
PGT-A Strongly RecommendedTwo or more failed IVF cycles despite good embryo quality — undetected aneuploidy is the most common hidden cause. PGT-A identifies why previous cycles failed and selects embryos that will implant.
PGT-A Recommended50–60% of miscarriages are caused by chromosomal abnormalities. PGT-A breaks the cycle of repeated loss by ensuring only chromosomally normal embryos are transferred.
PGT-A / PGT-SRCouples who are carriers of inherited genetic conditions — thalassaemia, cystic fibrosis, sickle cell, Huntington's, SMA, haemophilia, BRCA, and 200+ others. PGT-M prevents transmission.
PGT-M RequiredOne or both partners with a balanced translocation or chromosomal inversion — high rates of miscarriage and unbalanced pregnancies are transformed by PGT-SR selection of balanced embryos.
PGT-SR RequiredCouples without known issues who wish to maximise their chance of a healthy pregnancy from each IVF cycle — particularly those with limited embryos who want to transfer only the best.
PGT-A OptionalPGT requires specialist expertise, certified laboratories, and experienced genetic counsellors. Matrushri delivers all three.
We use Next Generation Sequencing — the most comprehensive and accurate PGT technology available — through certified partner genetic laboratories, with >99% accuracy across all 24 chromosomes.
PGT-A, PGT-M, and PGT-SR — all three types under one roof. Whether you need aneuploidy screening, single-gene disorder testing, or structural rearrangement analysis, we provide it all.
Every PGT patient receives pre-test and post-results genetic counselling — explaining what the results mean, the options available, and supporting informed decision-making throughout.
Trophectoderm biopsy is a highly delicate procedure requiring expert embryologists and a certified clean-room environment. Our Class 1000 lab provides the optimal setting for safe, precise biopsies.
PGT is not right for every patient. We advise honestly — recommending it only where the clinical evidence supports benefit for your specific situation, with clear explanation of costs and expected outcomes.
Genetics consultations are available across all Matrushri centres. IVF, biopsy, and FET procedures are performed at our specialist IVF units with full genetics program infrastructure.
Whether you need PGT-A, PGT-M, or PGT-SR — our genetics specialists are here to guide you. Book a free, confidential consultation today.
🔒 100% confidential. We never share your personal information.